Table Info

Table 1.

Predictors of disease progression and mortality

Conditions	Predictors
Progression	UIP pattern Extension in HRCT High ACPA values Degree of impairment in follow-up High serum IL-6 and KL-6
Mortality	Advanced age at diagnosis Male sex Duration and moderate-high activity of RA UIP pattern Low baseline DLCO and/or FVC ↓DLCO > 15% or ↓FVC > 10% during follow-up Extension in HRCT > 20–30% GAP and CPI High serum KL-6

Conditions

Predictors

Progression

UIP pattern

Extension in HRCT

High ACPA values

Degree of impairment in follow-up

High serum IL-6 and KL-6

Mortality

Advanced age at diagnosis

Male sex

Duration and moderate-high activity of RA

UIP pattern

Low baseline DLCO and/or FVC

↓DLCO > 15% or ↓FVC > 10% during follow-up

Extension in HRCT > 20–30%

GAP and CPI

High serum KL-6

↓: less; GAP: gender-age-physiology; CPI: composite physiologic index

Declarations

Acknowledgments

The authors thank the Spanish Foundation of Rheumatology for providing medical writing/editorial assistance during the preparation of the manuscript (FERBT2023).

Author contributions

GCR and VV: Conceptualization, Writing—original draft, Writing—review & editing. Both of the authors read and approved the submitted version.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

References

Xaubet A, Ancochea J, Blanquer R, Montero C, Moren E, Rodríguez Becerra E, et al. Diagnosis and treatment of diffuse interstitial lung diseases. Arch Bronconeumol. 2003;39:580–600. Spanish. [DOI] [PubMed]

American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med. 2002;165:277–304. Erratum in: Am J Respir Crit Care Med. 2002;166:426. [DOI] [PubMed]

Koduri G, Norton S, Young A, Cox N, Davies P, Devlin J, et al.; ERAS (Early Rheumatoid Arthritis Study). Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an inception cohort. Rheumatology (Oxford). 2010;49:1483–9. [DOI] [PubMed]

Guía de práctica clínica para el manejo de pacientes con artritis reumatoide [Internet]. Madrid: Sociedad Española de Reumatología; c2019 [cited 2021 Oct 30]. Available from: https://guipcar.ser.es

Bongartz T, Nannini C, Medina-Velasquez YF, Achenbach SJ, Crowson CS, Ryu JH, et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2010;62:1583–91. [DOI] [PubMed] [PMC]

Spagnolo P, Lee JS, Sverzellati N, Rossi G, Cottin V. The lung in rheumatoid arthritis: focus on interstitial lung disease. Arthritis Rheumatol. 2018;70:1544–54. [DOI] [PubMed]

Kelly CA, Saravanan V, Nisar M, Arthanari S, Woodhead FA, Price-Forbes AN, et al. Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics—a large multicentre UK study. Rheumatology (Oxford). 2014;53:1676–82. [DOI] [PubMed]

Yunt ZX, Solomon JJ. Lung disease in rheumatoid arthritis. Rheum Dis Clin North Am. 2015;41:225–36. [PubMed] [PMC]

Robles-Perez A, Luburich P, Rodriguez-Sanchon B, Dorca J, Nolla JM, Molina-Molina M, et al. Preclinical lung disease in early rheumatoid arthritis. Chron Respir Dis. 2016;13:75–81. [DOI] [PubMed] [PMC]

10.

Gabbay E, Tarala R, Will R, Carroll G, Adler B, Cameron D, et al. Interstitial lung disease in recent onset rheumatoid arthritis. Am J Respir Crit Care Med. 1997;156:528–35. [DOI] [PubMed]

11.

Habib HM, Eisa AA, Arafat WR, Marie MA. Pulmonary involvement in early rheumatoid arthritis patients. Clin Rheumatol. 2011;30:217–21. [DOI] [PubMed]

12.

Wilsher M, Voight L, Milne D, Teh M, Good N, Kolbe J, et al. Prevalence of airway and parenchymal abnormalities in newly diagnosed rheumatoid arthritis. Respir Med. 2012;106:1441–6. [DOI] [PubMed]

13.

Saag KG, Kolluri S, Koehnke RK, Georgou TA, Rachow JW, Hunninghake GW, et al. Rheumatoid arthritis lung disease. Determinant of radiographic and physiologic abnormalities. Arthritis Rheum. 1996;39:1711–9. [DOI] [PubMed]

14.

Sparks JA, He X, Huang J, Fletcher EA, Zaccardelli A, Friedlander HM, et al. Rheumatoid arthritis disease activity predicting incident clinically apparent rheumatoid arthritis- associated interstitial lung disease: a prospective cohort study. Arthritis Rheumatol. 2019;71:1472–82. [DOI] [PubMed] [PMC]

15.

Zhu J, Zhou Y, Chen X, Li J. A meta-analysis of the increased risk of rheumatoid arthritis-related pulmonary disease as a result of serum anticitrullinated protein antibody positivity. J Rheumatol. 2014;41:1282–9. [DOI] [PubMed]

16.

Chen J, Doyle TJ, Liu Y, Aggarwal R, Wang X, Shi Y, et al. Biomarkers of rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheumatol. 2015;67:28–38. [DOI] [PubMed] [PMC]

17.

Matsuo T, Hashimoto M, Ito I, Kubo T, Uozumi R, Furu M, et al. Interleukin-18 is associated with the presence of interstitial lung disease in rheumatoid arthritis: a cross-sectional study. Scand J Rheumatol. 2019;48:87–94. [DOI] [PubMed]

18.

Doyle TJ, Patel AS, Hatabu H, Nishino M, Wu G, Osorio JC, et al. Detection of rheumatoid arthritis-interstitial lung disease is enhanced by serum biomarkers. Am J Respir Crit Care Med. 2015;191:1403–12. [DOI] [PubMed] [PMC]

19.

Harlow L, Rosas IO, Gochuico BR, Mikuls TR, Dellaripa PF, Oddis CV, et al. Identification of citrullinated Hsp90 isoforms as novel autoantigens in rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheum. 2013;65:869–79. [DOI] [PubMed]

20.

Juge PA, Lee JS, Ebstein E, Furukawa H, Dobrinskikh E, Gazal S, et al. MUC5B promoter variant and rheumatoid arthritis with interstitial lung disease. N Engl J Med. 2018;379:2209–19. [DOI] [PubMed] [PMC]

21.

Juge PA, Borie R, Kannengiesser C, Gazal S, Revy P, Wemeau-Stervinou L, et al. Shared genetic predisposition in rheumatoid arthritis-interstitial lung disease and familial pulmonary fibrosis. Eur Respir J. 2017;49:1602314. [DOI] [PubMed]

22.

Newton CA, Oldham JM, Ley B, Anand V, Adegunsoye A, Liu G, et al. Telomere length and genetic variant associations with interstitial lung disease progression and survival. Eur Respir J. 2019;53:1801641. [DOI] [PubMed] [PMC]

23.

Antoniou KM, Margaritopoulos GA, Proklou A, Karagiannis K, Lasithiotaki I, Soufla G, et al. Investigation of telomerase/telomeres system in bone marrow mesenchymal stem cells derived from IPF and RA-UIP. J Inflamm (Lond). 2012;9:27. [DOI] [PubMed] [PMC]

24.

Li L, Liu R, Zhang Y, Zhou J, Li Y, Xu Y, et al. A retrospective study on the predictive implications of clinical characteristics and therapeutic management in patients with rheumatoid arthritis-associated interstitial lung disease. Clin Rheumatol. 2020;39:1457–70. [DOI] [PubMed]

25.

Mori S, Koga Y, Sugimoto M. Different risk factors between interstitial lung disease and airway disease in rheumatoid arthritis. Respir Med. 2012;106:1591–9. [DOI] [PubMed]

26.

Zhang Y, Li H, Wu N, Dong X, Zheng Y. Retrospective study of the clinical characteristics and risk factors of rheumatoid arthritis-associated interstitial lung disease. Clin Rheumatol. 2017;36:817–23. [DOI] [PubMed]

27.

Lee YS, Kim HC, Lee BY, Lee CK, Kim MY, Jang SJ, et al. The value of biomarkers as predictors of outcome in patients with rheumatoid arthritis-associated usual interstitial pneumonia. Sarcoidosis Vasc Diffuse Lung Dis. 2016;33:216–23. [PubMed]

28.

Solomon JJ, Ryu JH, Tazelaar HD, Myers JL, Tuder R, Cool CD, et al. Fibrosing interstitial pneumonia predicts survival in patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD). Respir Med. 2013;107:1247–52. [DOI] [PubMed]

29.

Yang JA, Lee JS, Park JK, Lee EB, Song YW, Lee EY. Clinical characteristics associated with occurrence and poor prognosis of interstitial lung disease in rheumatoid arthritis. Korean J Intern Med. 2019;34:434–41. [DOI] [PubMed] [PMC]

30.

Song JW, Lee HK, Lee CK, Chae EJ, Jang SJ, Colby TV, et al. Clinical course and outcome of rheumatoid arthritis-related usual interstitial pneumonia. Sarcoidosis Vasc Diffuse Lung Dis. 2013;30:103–12. [PubMed]

31.

Rojas-Serrano J, Herrera-Bringas D, Pérez-Román DI, Pérez-Dorame R, Mateos-Toledo H, Mejía M. Rheumatoid arthritis-related interstitial lung disease (RA-ILD): methotrexate and the severity of lung disease are associated to prognosis. Clin Rheumatol. 2017;36:1493–500. [DOI] [PubMed]

32.

Zamora-Legoff JA, Krause ML, Crowson CS, Ryu JH, Matteson EL. Patterns of interstitial lung disease and mortality in rheumatoid arthritis. Rheumatology (Oxford). 2017;56:344–50. [DOI] [PubMed] [PMC]

33.

Kim HC, Choi KH, Jacob J, Song JW. Prognostic role of blood KL-6 in rheumatoid arthritis-associated interstitial lung disease. PLoS One. 2020;15:e0229997. [DOI] [PubMed] [PMC]

34.

Kakutani T, Hashimoto A, Tominaga A, Kodama K, Nogi S, Tsuno H, et al. Related factors, increased mortality and causes of death in patients with rheumatoid arthritis-associated interstitial lung disease. Mod Rheumatol. 2020;30:458–64. [DOI] [PubMed]

35.

Hyldgaard C, Ellingsen T, Hilberg O, Bendstrup E. Rheumatoid arthritis-associated interstitial lung disease: clinical characteristics and predictors of mortality. Respiration. 2019;98:455–60. [DOI] [PubMed]

36.

Solomon JJ, Chung JH, Cosgrove GP, Demoruelle MK, Fernandez-Perez ER, Fischer A, et al. Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J. 2016;47:588–96. [DOI] [PubMed]

37.

Morisset J, Vittinghoff E, Lee BY, Tonelli R, Hu X, Elicker BM, et al. The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease. Respir Med. 2017;127:51–6. [DOI] [PubMed] [PMC]

38.

Assayag D, Lubin M, Lee JS, King TE, Collard HR, Ryerson CJ. Predictors of mortality in rheumatoid arthritis-related interstitial lung disease. Respirology. 2014;19:493–500. [DOI] [PubMed]

39.

Singh N, Varghese J, England BR, Solomon JJ, Michaud K, Mikuls TR, et al. Impact of the pattern of interstitial lung disease on mortality in rheumatoid arthritis: a systematic literature review and meta-analysis. Semin Arthritis Rheum. 2019;49:358–65. [DOI] [PubMed]

40.

Nurmi HM, Kettunen HP, Suoranta SK, Purokivi MK, Kärkkäinen MS, Selander TA, et al. Several high-resolution computed tomography findings associate with survival and clinical features in rheumatoid arthritis-associated interstitial lung disease. Respir Med. 2018;134:24–30. [DOI] [PubMed]

41.

Salaffi F, Carotti M, Di Carlo M, Tardella M, Giovagnoni A. High-resolution computed tomography of the lung in patients with rheumatoid arthritis: prevalence of interstitial lung disease involvement and determinants of abnormalities. Medicine (Baltimore). 2019;98:e17088. [DOI] [PubMed] [PMC]

42.

Ito Y, Arita M, Kumagai S, Takei R, Noyama M, Tokioka F, et al. Radiological fibrosis score is strongly associated with worse survival in rheumatoid arthritis-related interstitial lung disease. Mod Rheumatol. 2019;29:98–104. [DOI] [PubMed]

43.

Dawson JK, Fewins HE, Desmond J, Lynch MP, Graham DR. Predictors of progression of HRCT diagnosed fibrosing alveolitis in patients with rheumatoid arthritis. Ann Rheum Dis. 2002;61:517–21. [DOI] [PubMed] [PMC]

44.

Li L, Gao S, Fu Q, Liu R, Zhang Y, Dong X, et al. A preliminary study of lung abnormalities on HRCT in patients of rheumatoid arthritis-associated interstitial lung disease with progressive fibrosis. Clin Rheumatol. 2019;38:3169–78. [DOI] [PubMed]

45.

Fu Q, Wang L, Li L, Li Y, Liu R, Zheng Y. Risk factors for progression and prognosis of rheumatoid arthritis-associated interstitial lung disease: single center study with a large sample of Chinese population. Clin Rheumatol. 2019;38:1109–16. [DOI] [PubMed]

46.

Giles JT, Danoff SK, Sokolove J, Wagner CA, Winchester R, Pappas DA, et al. Association of fine specificity and repertoire expansion of anticitrullinated peptide antibodies with rheumatoid arthritis associated interstitial lung disease. Ann Rheum Dis. 2014;73:1487–94. [DOI] [PubMed] [PMC]

47.

Yin Y, Liang D, Zhao L, Li Y, Liu W, Ren Y, et al. Anti-cyclic citrullinated peptide antibody is associated with interstitial lung disease in patients with rheumatoid arthritis. PLoS One. 2014;9:e92449. [DOI] [PubMed] [PMC]

48.

Zamora-Legoff JA, Krause ML, Crowson CS, Ryu JH, Matteson EL. Progressive decline of lung function in rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheumatol. 2017;69:542–9. [DOI] [PubMed] [PMC]

49.

Farquhar H, Vassallo R, Edwards AL, Matteson EL. Pulmonary complications of rheumatoid arthritis. Semin Respir Crit Care Med. 2019;40:194–207. [DOI] [PubMed]

50.

Kim EJ, Elicker BM, Maldonado F, Webb WR, Ryu JH, Van Uden JH, et al. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J. 2010;35:1322–8. [DOI] [PubMed]

51.

Tsuchiya Y, Takayanagi N, Sugiura H, Miyahara Y, Tokunaga D, Kawabata Y, et al. Lung diseases directly associated with rheumatoid arthritis and their relationship to outcome. Eur Respir J. 2011;37:1411–7. [DOI] [PubMed]

52.

Nieto MA, Rodriguez-Nieto MJ, Sanchez-Pernaute O, Romero-Bueno F, Leon L, Vadillo C, et al. Mortality rate in rheumatoid arthritis-related interstitial lung disease: the role of radiographic patterns. BMC Pulm Med. 2021;21:205. [DOI] [PubMed] [PMC]

53.

Yunt ZX, Chung JH, Hobbs S, Fernandez-Perez ER, Olson AL, Huie TJ, et al. High resolution computed tomography pattern of usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease: Relationship to survival. Respir Med. 2017;126:100–4. [DOI] [PubMed]

54.

Hozumi H, Nakamura Y, Johkoh T, Sumikawa H, Colby TV, Kono M, et al. Acute exacerbation in rheumatoid arthritis-associated interstitial lung disease: a retrospective case control study. BMJ Open. 2013;3:e003132. [DOI] [PubMed] [PMC]

55.

Gochuico BR, Avila NA, Chow CK, Novero LJ, Wu HP, Ren P, et al. Progressive preclinical interstitial lung disease in rheumatoid arthritis. Arch Intern Med. 2008;168:159–66. [DOI] [PubMed]

56.

Doyle TJ, Dellaripa PF, Batra K, Frits ML, Iannaccone CK, Hatabu H, et al. Functional impact of a spectrum of interstitial lung abnormalities in rheumatoid arthritis. Chest. 2014;146:41–50. [DOI] [PubMed] [PMC]

57.

Rodríguez Portal JA, Brito García N, Díaz del Campo Fontecha P, Valenzuela C, Ortiz AM, Nieto MA, et al. Recomendaciones SER-SEPAR sobre el manejo de la enfermedad pulmonar intersticial difusa asociada a la artritis reumatoide. Parte 1: epidemiología, factores de riesgo y pronóstico. Reumatol Clin. 2022;18:443–52. Spanish. [DOI]

58.

Narváez J, Aburto M, Seoane-Mato D, Bonilla G, Acosta O, Candelas G, et al. Criterios de cribado de la enfermedad pulmonar intersticial difusa asociada a la artritis reumatoide: Propuesta de expertos basada en metodología Delphi. Reumatol Clin. 2023;19:74–81. Spanish. [DOI]

59.

Mink SN, Maycher B. Comparative manifestations and diagnostic accuracy of high-resolution computed tomography in usual interstitial pneumonia and nonspecific interstitial pneumonia. Curr Opin Pulm Med. 2012;18:530–4. [DOI] [PubMed]

60.

Garcia JG, Parhami N, Killam D, Garcia PL, Keogh BA. Bronchoalveolar lavage fluid evaluation in rheumatoid arthritis. Am Rev Respir Dis. 1986;133:450–4. [PubMed]

61.

Fischer A, Lee JS, Cottin V. Interstitial lung disease evaluation: detecting connective tissue disease. Respiration. 2015;90:177–84. [DOI] [PubMed]

62.

Iqbal K, Kelly C. Treatment of rheumatoid arthritis-associated interstitial lung disease: a perspective review. Ther Adv Musculoskelet Dis. 2015;7:247–67. [DOI] [PubMed] [PMC]

63.

Wells AU, Hirani N; British Thoracic Society Interstitial Lung Disease Guideline Group; British Thoracic Society Standards of Care Committee; Thoracic Society of Australia; New Zealand Thoracic Society; Irish Thoracic Society. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax. 2008;63:v1–58. Erratum in: Thorax. 2008;63:1029. [DOI] [PubMed]

64.

Fragoulis GE, Nikiphorou E, Larsen J, Korsten P, Conway R. Methotrexate-associated pneumonitis and rheumatoid arthritis-interstitial lung disease: current concepts for the diagnosis and treatment. Front Med (Lausanne). 2019;6:238. [DOI] [PubMed] [PMC]

65.

Kiely P, Busby AD, Nikiphorou E, Sullivan K, Walsh DA, Creamer P, et al. Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts. BMJ Open. 2019;9:e028466. [DOI] [PubMed] [PMC]

66.

Conway R, Low C, Coughlan RJ, O’Donnell MJ, Carey JJ. Methotrexate and lung disease in rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheumatol. 2014;66:803–12. [DOI] [PubMed]

67.

Sawada T, Inokuma S, Sato T, Otsuka T, Saeki Y, Takeuchi T, et al.; Study Committee for Leflunomide-induced Lung Injury; Japan College of Rheumatology. Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis. Rheumatology (Oxford). 2009;48:1069–72. [DOI] [PubMed]

68.

Nakashita T, Ando K, Kaneko N, Takahashi K, Motojima S. Potential risk of TNF inhibitors on the progression of interstitial lung disease in patients with rheumatoid arthritis. BMJ Open. 2014;4:e005615. [DOI] [PubMed] [PMC]

69.

Kang EH, Jin Y, Desai RJ, Liu J, Sparks JA, Kim SC. Risk of exacerbation of pulmonary comorbidities in patients with rheumatoid arthritis after initiation of abatacept versus TNF inhibitors: a cohort study. Semin Arthritis Rheum. 2020;50:401–8. [DOI] [PubMed]

70.

Curtis JR, Sarsour K, Napalkov P, Costa LA, Schulman KL. Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor α agents, a retrospective cohort study. Arthritis Res Ther. 2015;17:319. [PubMed] [PMC]

71.

Dixon WG, Hyrich KL, Watson KD, Lunt M, Symmons DPM; BSRBR Control Centre Consortium; British Society for Rheumatology Biologics Register. Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2010;69:1086–91. Erratum in: Ann Rheum Dis. 2011;70:1519. [DOI] [PubMed] [PMC]

72.

Huang Y, Lin W, Chen Z, Wang Y, Huang Y, Tu S. Effect of tumor necrosis factor inhibitors on interstitial lung disease in rheumatoid arthritis: angel or demon? Drug Des Devel Ther. 2019;13:2111–25. [DOI] [PubMed] [PMC]

73.

Fernández-Díaz C, Loricera J, Castañeda S, López-Mejías R, Ojeda-García C, Olivé A, et al. Abatacept in patients with rheumatoid arthritis and interstitial lung disease: a national multicenter study of 63 patients. Semin Arthritis Rheum. 2018;48:22–7. [DOI] [PubMed]

74.

Fernández-Díaz C, Castañeda S, Melero-González RB, Ortiz-Sanjuán F, Juan-Mas A, Carrasco-Cubero C, et al. Abatacept in interstitial lung disease associated with rheumatoid arthritis: national multicenter study of 263 patients. Rheumatology (Oxford). 2020;59:3906–16. [DOI] [PubMed]

75.

Vicente-Rabaneda EF, Atienza-Mateo B, Blanco R, Cavagna L, Ancochea J, Castañeda S, et al. Efficacy and safety of abatacept in interstitial lung disease of rheumatoid arthritis: a systematic literature review. Autoimmun Rev. 2021;20:102830. [DOI] [PubMed]

76.

Nakashita T, Ando K, Takahashi K, Motojima S. Possible effect of abatacept on the progression of interstitial lung disease in rheumatoid arthritis patients. Respir Investig. 2016;54:376–9. [DOI] [PubMed]

77.

Md Yusof MY, Kabia A, Darby M, Lettieri G, Beirne P, Vital EM, et al. Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years’ experience at a single centre. Rheumatology (Oxford). 2017;56:1348–57. [DOI] [PubMed] [PMC]

78.

Vadillo C, Nieto MA, Romero-Bueno F, Leon L, Sanchez-Pernaute O, Rodriguez-Nieto MJ, et al. Efficacy of rituximab in slowing down progression of rheumatoid arthritis-related interstitial lung disease: data from the NEREA Registry. Rheumatology (Oxford). 2020;59:2099–108. [DOI] [PubMed]

79.

Kelly CA, Nisar M, Arthanari S, Carty S, Woodhead FA, Price-Forbes A, et al. Rheumatoid arthritis related interstitial lung disease – improving outcomes over 25 years: a large multicentre UK study. Rheumatology (Oxford). 2021;60:1882–90. [DOI] [PubMed]

80.

Manfredi A, Cassone G, Furini F, Gremese E, Venerito V, Atzeni F, et al. Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicentre retrospective study. Intern Med J. 2020;50:1085–90. [DOI] [PubMed]

81.

Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, et al. Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan. J Rheumatol. 2014;41:15–23. [DOI] [PubMed]

82.

Roubille C, Haraoui B. Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review. Semin Arthritis Rheum. 2014;43:613–26. [DOI] [PubMed]

83.

Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, et al.; INBUILD Trial Investigators. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381:1718–27. [DOI] [PubMed]

84.

Solomon JJ, Danoff SK, Goldberg HJ, Woodhead F, Kolb M, Chambers DC, et al.; Trail Network. The design and rationale of the Trail1 trial: a randomized double-blind phase 2 clinical trial of pirfenidone in rheumatoid arthritis-associated interstitial lung disease. Adv Ther. 2019;36:3279–87. [DOI] [PubMed]

85.

Vacchi C, Manfredi A, Cassone G, Salvarani C, Cerri S, Sebastiani M. Combination therapy with nintedanib and sarilumab for the management of rheumatoid arthritis related interstitial lung disease. Case Rep Med. 2020;2020:6390749. [DOI] [PubMed] [PMC]

86.

Kakuwa T, Izumi S, Sakamoto K, Suzuki T, Iikura M, Sugiyama H. A successful treatment of rheumatoid arthritis-related interstitial pneumonia with nintedanib. Respir Med Case Rep. 2018;26:50–2. [DOI] [PubMed] [PMC]

87.

Narváez J, Vicens-Zygmunt V, Alegre JJ, Herrera-Lara S, Nolla JM, Molina-Molina M. Nintedanib for the treatment of refractory progressive rheumatoid arthritis-related interstitial lung disease: a real-life case series. Rheumatology (Oxford). 2020;59:3983–6. [DOI] [PubMed]

88.

Holroyd CR, Seth R, Bukhari M, Malaviya A, Holmes C, Curtis E, et al. The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis. Rheumatology (Oxford). 2019;58:e3–42. Erratum in: Rheumatology (Oxford). 2019;58:372. [DOI] [PubMed]

89.

Yazdani A, Singer LG, Strand V, Gelber AC, Williams L, Mittoo S. Survival and quality of life in rheumatoid arthritis–associated interstitial lung disease after lung transplantation. J Heart Lung Transplant. 2014;33:514–20. [DOI] [PubMed]

90.

Caminati A, Cassandro R, Harari S. Pulmonary hypertension in chronic interstitial lung diseases. Eur Respir Rev. 2013;22:292–301. [PubMed] [PMC]